Introduction
Familial Hypercholesterolaemia (FH) Arrays I & II are diagnostic tools designed for the rapid and simultaneous detection of 40 mutations within the LDLR, ApoB, and PCSK9 genes. These arrays facilitate the genetic assessment of patients suspected of having FH, a genetic disorder affecting lipoprotein metabolism and increasing cardiovascular disease risk.

Specifications
The FH Arrays I & II utilize multiplex PCR and biochip array hybridization, allowing for high specificity and rapid analysis, with results available in approximately 3 hours. Each array detects 20 mutations, covering a total of 40 mutations associated with FH.

Clinical Data
Validation studies demonstrated a 98% correlation in detecting FH mutations using these arrays. The prevalence of FH is estimated at 1 in 250, highlighting the importance of early diagnosis and treatment to prevent premature cardiac events.

Procedures
The testing process involves four main steps: extraction of genomic DNA from blood, amplification via multiplex PCR, hybridization to a biochip array, and detection using an analyzer. This streamlined process allows for efficient and cost-effective testing.

Benefits
Laboratory Benefits: The arrays provide a targeted, cost-effective assay with rapid turnaround times, reducing the need for comprehensive genetic analysis.
Patient Benefits: Rapid determination of mutational status from a single test enhances diagnostic accuracy and reduces the need for confirmatory testing.

Recommendations
The UK National Institute for Health and Clinical Excellence (NICE) recommends DNA testing for all FH patients to confirm diagnosis and facilitate cascade testing of relatives. Despite the cost-effectiveness of national genetic screening programs, few countries have implemented them.

Product Features
The FH Arrays require only 20ng of genomic DNA per array and can process small batches of samples, making them suitable for various laboratory settings.

Conclusion
Randox Molecular's FH Arrays I & II offer precise diagnostics for targeted therapy, enabling healthcare practitioners to predict, prevent, and treat FH effectively.